Clinical Trials available now!
Explore

Cequa Patent Expiration

Cequa is a drug owned by Sun Pharmaceutical Industries Ltd. It is protected by 5 US drug patents filed from 2018 to 2024 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Feb 28, 2037. Details of Cequa's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11951153 Topical cyclosporine-containing formulations and uses thereof
Feb, 2037

(12 years from now)

Active
US10918694 Topical cyclosporine-containing formulations and uses thereof
Feb, 2037

(12 years from now)

Active
US8980839 Topical aqueous nanomicellar, ophthalmic solutions and uses thereof
Aug, 2033

(8 years from now)

Active
US9937225 Topical formulations and uses thereof
Aug, 2033

(8 years from now)

Active
US10441630 Topical formulations and uses thereof
Aug, 2033

(8 years from now)

Active


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Cequa's patents.

Given below is the list of recent legal activities going on the following patents of Cequa.

Activity Date Patent Number
Patent litigations
Electronic Review 07 Jun, 2024 US11951153
Patent eGrant Notification 09 Apr, 2024 US11951153
Recordation of Patent Grant Mailed 09 Apr, 2024 US11951153
Recordation of Patent eGrant 09 Apr, 2024 US11951153
Email Notification 09 Apr, 2024 US11951153
Mail Patent eGrant Notification 09 Apr, 2024 US11951153
Patent Issue Date Used in PTA Calculation 09 Apr, 2024 US11951153
Email Notification 21 Mar, 2024 US11951153
Issue Notification Mailed 20 Mar, 2024 US11951153
Email Notification 07 Mar, 2024 US11951153

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Cequa is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Cequa's family patents as well as insights into ongoing legal events on those patents.

Cequa's Family Patents

Cequa has patent protection in a total of 14 countries. It's US patent count contributes only to 44.4% of its total global patent coverage. 2 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree for Cequa.

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Clinical Trials

Recent Clinical Trials on Cequa:

Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry. Cequa(Cyclosporine) has 1 clinical trial that has been verified in 2024.

Title Lead Sponsor Collaborators Status Phases
Combination of Eltrombopag With Immunosuppressive Therapy in East-Asian Patients With Severe Aplastic Anemia Novartis Pharmaceuticals ACTIVE NOT RECRUITING
(Oct, 2024)
PHASE2
The Effect of Cyclosporin Before Cataract Surgery Samsung Medical Center COMPLETED
(May, 2022)
PHASE4
Efficacy and Safety of Lenalidomide in Combination With Cyclosporine A in Patients With Myelodysplastic Syndromes Weill Medical College of Cornell University Celgene TERMINATED
(Nov, 2019)
PHASE2
Investigation of Flare and Remission in Subjects With Atopic Dermatitis LEO Pharma WITHDRAWN
(Jul, 2019)
PHASE4
Ciclosporin in the Management of Chronic or Recurrent Erythema Nodosum Leprosum London School of Hygiene and Tropical Medicine Homes and Hospitals of St Giles, Alert Hospital, Ethiopia, Armauer Hansen Research Institute, Ethiopia COMPLETED
(Mar, 2015)
PHASE2
Restasis for Treatment of Brittle Nails Julian M. Mackay-Wiggan Allergan COMPLETED
(Jul, 2013)
PHASE2
Cyclosporine Inhalation Solution (CIS) in Lung Transplant Recipients APT Pharmaceuticals, Inc. NO LONGER AVAILABLE
(Sep, 2012)
Efficacy and Safety of Everolimus in Recipients of Heart Transplants to Prevent Acute and Chronic Rejection Novartis Pharmaceuticals COMPLETED
(Jul, 2012)
PHASE3
Cyclosporine Dose Adjustment According to Calcineurin Activity After Allogeneic Hematopoietic Stem-cell Transplantation Assistance Publique - Hôpitaux de Paris Agence de La Biomédecine COMPLETED
(Jul, 2009)
PHASE2
Low Dose Cyclosporin and Methotrexate Therapy in Diabetes Georgetown University COMPLETED
(May, 2009)
NA




Generic Launch

Generic Release Date:

Cequa's generic launch date based on the expiry of its last outstanding patent is estimated to be Feb 28, 2037 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Cequa Generics:

Cyclosporine is the generic name for the brand Cequa. 14 different companies have already filed for the generic of Cequa, with Apotex having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Cequa's generic

Alternative Brands for Cequa

Cequa which is used for increasing tear production in patients with dry eye (keratoconjunctivitis sicca)., has several other brand drugs in the same treatment category and using the same active ingredient (Cyclosporine). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.

Drug Owner Drug Name Treatment Area
Abbvie
Restasis

(uses Cyclosporine)

Used for increasing tear production in patients with keratoconjunctivitis sicca (dry eye).
Restasis Multidose

(uses Cyclosporine)

Used for treating dry eye by increasing tear production in patients with keratoconjunctivitis sicca.
Harrow Eye
Vevye

(uses Cyclosporine)

Used for managing symptoms of dry eye disease.

Apart from drugs working in same treatment category, there are also some brand drugs where treatment area is different, but the active ingredient used is same i.e. Cyclosporine. Given below is the list of those drugs and companies owning them.

Drug Owner Drug Name
Harrow Eye
Verkazia
Novartis
Neoral


Apart from brand drugs containing the same ingredient, some generics have also been filed for Cyclosporine, Cequa's active ingredient. Check the complete list of approved generic manufacturers for Cequa





About Cequa

Cequa is a drug owned by Sun Pharmaceutical Industries Ltd. It is used for increasing tear production in patients with dry eye (keratoconjunctivitis sicca). Cequa uses Cyclosporine as an active ingredient. Cequa was launched by Sun Pharm in 2018.

Approval Date:

Cequa was approved by FDA for market use on 14 August, 2018.

Active Ingredient:

Cequa uses Cyclosporine as the active ingredient. Check out other Drugs and Companies using Cyclosporine ingredient

Treatment:

Cequa is used for increasing tear production in patients with dry eye (keratoconjunctivitis sicca).

Dosage:

Cequa is available in solution form for ophthalmic use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
0.09% SOLUTION Prescription OPHTHALMIC